Stimuli-Sensitive Nanotherapies for the Treatment of Osteoarthritis

Macromol Biosci. 2021 Nov;21(11):e2100280. doi: 10.1002/mabi.202100280. Epub 2021 Aug 16.

Abstract

Osteoarthritis (OA) is a common chronic inflammatory disease in the joints. It is one of the leading causes of disability with increasing morbidity, which has become one of the serious clinical issues. Current treatments would only provide temporary relief due to the lack of early diagnosis and effective therapy, and thus the replacement of joints may be needed when the OA deteriorates. Although the intra-articular injection and oral administration of drugs are helpful for OA treatment, they are suffering from systemic toxicity, short retention time in joint, and insufficient bioavailability. Nanomedicine is potential to improve the drug delivery efficiency and targeting ability. In this focused progress review, the particle-based drug loading systems that can achieve targeted and triggered release are summarized. Stimuli-responsive nanocarriers that are sensitive to endogenous microenvironmental signals such as reactive oxygen species, enzymes, pH, and temperature, as well as external stimuli such as light for OA therapy are introduced in this review. Furthermore, the nanocarriers associated with targeted therapy and imaging for OA treatment are summarized. The potential applications of nanotherapies for OA treatment are finally discussed.

Keywords: drug delivery; nanomedicine; osteoarthritis; reactive oxygen species; stimuli-responsive.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Biological Availability
  • Drug Delivery Systems / methods
  • Humans
  • Nanomedicine*
  • Osteoarthritis / drug therapy*